I believe the gist of it is: FDA is willing to accept new potency data generated to pave the way for FDA to consider pH 3 trial MAB-GVHD001 gor paediatrics as adequate study. I think (a) a few months is quite a good time frame for a potentially significant outcome.
Re adults, a 12 month controlled single arm is also quite a reasonable outcome and given the data and evidence already, that should be a matter of ticking the box ... something FDA likes.
So, much better than we could have potentially ntcipated.
Ann: Mesoblast Type A Meeting with FDA, page-8
-
- There are more pages in this discussion • 567 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |